biosimilars

J&J warns generics will bite its pharma unit in the second half
J&J warns generics will bite its pharma unit in the second half
Pharmaforum
JNJ
generics
biosimilars
Darzalex
Zytiga
Flag link:
Biosimilars Continue To Exhibit Market Failure
Biosimilars Continue To Exhibit Market Failure
Forbes
biosimilars
Flag link:
Why AbbVie's Stock Sank in the First Half of 2019
Why AbbVie's Stock Sank in the First Half of 2019
Motley Fool
AbbVie
Humira
biosimilars
M&A
Allergan
Flag link:
Another Biosimilar Approval From FDA, Another Unknown Launch Date
Another Biosimilar Approval From FDA, Another Unknown Launch Date
RAPS.org
Pfizer
Zirabev
biosimilars
FDA
Roche
cancer
Avastin
Flag link:
Samsung Bioepis CEO urges patience as US biosimilar market lags
Samsung Bioepis CEO urges patience as US biosimilar market lags
BioPharma Dive
biosimilars
Samsung Bioepis
Flag link:
FDA Approves 20th Biosimilar, 5th for Roche’s Herceptin
FDA Approves 20th Biosimilar, 5th for Roche’s Herceptin
RAPS.org
FDA
biosimilars
Roche
Herceptin
Amgen
Kanjinti
Flag link:
Iranian drugmaker opens $100M plant in Turkey, will make Humira biosimilar
Iranian drugmaker opens $100M plant in Turkey, will make Humira biosimilar
Fierce Pharma
Turkey
Iran
Humira
biosimilars
CinnaGen Pharmaceuticals
Flag link:
FDA Replaces Withdrawn Biosimilar Guidance With New One on Quality-Related Considerations
FDA Replaces Withdrawn Biosimilar Guidance With New One on Quality-Related Considerations
RAPS.org
FDA
biosimilars
Flag link:
Anything You Can Do I Can Do (Better?): Demonstrating Biosimilar Interchangeability
Anything You Can Do I Can Do (Better?): Demonstrating Biosimilar Interchangeability
FDA Law Blog
FDA
biosimilars
interchangeability
Flag link:
AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.
AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.
Marketwatch
AbbVie
biosimilars
Humira
patents
Boehringer Ingelheim
Flag link:
Interchangeable Insulins: FDA Holds Public Meeting
Interchangeable Insulins: FDA Holds Public Meeting
RAPS.org
diabetes
insulin
biosimilars
FDA
biosimilar insulin
Flag link:
House Unanimously Passes Bills Updating FDA’s Orange and Purple Books
House Unanimously Passes Bills Updating FDA’s Orange and Purple Books
RAPS.org
Orange Book
generics
Purple Book
biosimilars
FDA
Flag link:
Pfizer Calls for Compromise on Retroactively Using Suffixes in Biologic Names
Pfizer Calls for Compromise on Retroactively Using Suffixes in Biologic Names
RAPS.org
Pfizer
FDA
suffixes
drug names
biologics
biosimilars
Flag link:
House Judiciary Committee Advances Four Bills Targeted at Generic Competition
House Judiciary Committee Advances Four Bills Targeted at Generic Competition
RAPS.org
generics
CREATES Act
biosimilars
Flag link:
FDA Approves 19th Biosimilar, 2nd for Enbrel
FDA Approves 19th Biosimilar, 2nd for Enbrel
RAPS.org
FDA
Samsung Bioepis
Eticovo
biosimilars
Amgen
Enbrel
Flag link:
Say goodbye to AbbVie's ever-growing Humira sales: The biosim decline has officially begun
Say goodbye to AbbVie's ever-growing Humira sales: The biosim decline has officially begun
Fierce Pharma
AbbVie
Humira
biosimilars
earnings
Flag link:
Gottlieb, biosimilars companies and consultants reject price control proposal
Gottlieb, biosimilars companies and consultants reject price control proposal
BioCentury
biosimilars
drug pricing
FDA
Scott Gottlieb
Flag link:
Biopharma CEOs Explain Problems With Biosimilars to Congress
Biopharma CEOs Explain Problems With Biosimilars to Congress
RAPS.org
biosimilars
Pharma CEOs
Flag link:
Generics would get a new boost from bipartisan bills
Generics would get a new boost from bipartisan bills
BioCentury
Senate
generics
biosimilars
competition
legislation
Flag link:
Coherus' Neulasta biosimilar surprises with strong early uptake
Coherus' Neulasta biosimilar surprises with strong early uptake
Biopharma Dive
Coherus Biosciences
Neulasta
biosimilars
Udenyca
Amgen
Flag link:

Pages